Formyl peptide receptor modulators: a patent review and potential applications for inflammatory diseases (2021–2024)

We examine newly disclosed patents concerning FPR modulators, with all specified compounds classified as either FPR1 or FPR2 modulators. Receptor cross-reactivity, ligand promiscuity, and receptor variations across species are challenges encountered during drug formulation. Further research into different types of biased agonists and the synthesis of potent and selective ligands is essential to overcome these obstacles and facilitate the eventual therapeutic use of biased signaling in inflammation and diseases.